 |
|
|
| |
PRO 140 (leronlimab) SC: Long-Acting Single-Agent Maintenance Therapy (SAMT) for HIV-1 Infection
|
| |
| |
Reported by Jules Levin
CROI 2019 March 4-7 Seattle
Kush Dhody1, Kazem Kazempour1, Nader Pourhassan2and Paul J. Maddon3
1Amarex Clinical Research, LLC, Germantown, MD 2CytoDyn Inc., Vancouver, WA, 3Maddon Advisors LLC, Scarsdale, NY
"Now that response rates for higher doses are more closely aligned with standard of care, in combination with its excellent safety profile, PRO140 (leronlimab) could be a paradigm shift in the treatment of HIV as a single-agent maintenance therapy."
|
| |
|
|
|
|
|
